Carter-Wallace
Executive Summary
Sales of the anticonvulsant Felbatol "were greater than planned" in company's fiscal nine months ended Dec. 31, company says in quarterly report. Carter-Wallace sales were $489.5 mil., up 1.1% for the period
Sales of the anticonvulsant Felbatol "were greater than planned" in company's fiscal nine months ended Dec. 31, company says in quarterly report. Carter-Wallace sales were $489.5 mil., up 1.1% for the period. |